These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. Amsterdam JD J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131 [TBL] [Abstract][Full Text] [Related]
3. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. Feiger AD; Rickels K; Rynn MA; Zimbroff DL; Robinson DS J Clin Psychiatry; 2006 Sep; 67(9):1354-61. PubMed ID: 17017821 [TBL] [Abstract][Full Text] [Related]
4. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Mann JJ; Aarons SF; Wilner PJ; Keilp JG; Sweeney JA; Pearlstein T; Frances AJ; Kocsis JH; Brown RP Arch Gen Psychiatry; 1989 Jan; 46(1):45-50. PubMed ID: 2491941 [TBL] [Abstract][Full Text] [Related]
5. l-Deprenyl in atypical depressives. Quitkin FM; Liebowitz MR; Stewart JW; McGrath PJ; Harrison W; Rabkin JG; Markowitz J; Davies SO Arch Gen Psychiatry; 1984 Aug; 41(8):777-81. PubMed ID: 6430257 [TBL] [Abstract][Full Text] [Related]
6. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Bodkin JA; Amsterdam JD Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221 [TBL] [Abstract][Full Text] [Related]
7. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. Amsterdam JD; Bodkin JA J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814 [TBL] [Abstract][Full Text] [Related]
8. Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS). Jang S; Jung S; Pae C; Kimberly BP; Craig Nelson J; Patkar AA J Affect Disord; 2013 Dec; 151(3):854-9. PubMed ID: 24021959 [TBL] [Abstract][Full Text] [Related]
9. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males. Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; Darnow J; Azzaro AJ; DiSanto AR J Clin Pharmacol; 1997 Mar; 37(3):238-47. PubMed ID: 9089426 [TBL] [Abstract][Full Text] [Related]
10. L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition. Tariot PN; Cohen RM; Sunderland T; Newhouse PA; Yount D; Mellow AM; Weingartner H; Mueller EA; Murphy DL Arch Gen Psychiatry; 1987 May; 44(5):427-33. PubMed ID: 3107514 [TBL] [Abstract][Full Text] [Related]
11. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Bodkin JA; Siris SG; Bermanzohn PC; Hennen J; Cole JO Am J Psychiatry; 2005 Feb; 162(2):388-90. PubMed ID: 15677608 [TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression. Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348 [TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic, and healthy control subjects. Redmond DE; Katz MM; Maas JW; Swann A; Casper R; Davis JM Arch Gen Psychiatry; 1986 Oct; 43(10):938-47. PubMed ID: 2428328 [TBL] [Abstract][Full Text] [Related]
15. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190 [TBL] [Abstract][Full Text] [Related]
16. The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPS, HIAA, and HVA levels of cerebrospinal fluid. Przuntek H; Kuhn W Adv Neurol; 1990; 53():445-9. PubMed ID: 1700583 [No Abstract] [Full Text] [Related]
17. Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect? Mendis N; Pare CM; Sandler M; Glover V; Stern GM Psychopharmacology (Berl); 1981; 73(1):87-90. PubMed ID: 6785797 [TBL] [Abstract][Full Text] [Related]
18. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Jarrett RB; Schaffer M; McIntire D; Witt-Browder A; Kraft D; Risser RC Arch Gen Psychiatry; 1999 May; 56(5):431-7. PubMed ID: 10232298 [TBL] [Abstract][Full Text] [Related]
19. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Peet M; Horrobin DF Arch Gen Psychiatry; 2002 Oct; 59(10):913-9. PubMed ID: 12365878 [TBL] [Abstract][Full Text] [Related]
20. Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid: II. Suicide. Agren H Psychiatry Res; 1980 Oct; 3(2):225-36. PubMed ID: 6171841 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]